RXi Pharmaceuticals,Thera Neuropharma Enter into Exclusive License Agreement for RXi's Self-Delivering RNAi Platform Targeting SOD1 to Develop Therapeutics for Neurodegenerative Diseases, Such as ALS
Charles Gross